logo-loader
Avacta Group PLC

Avacta Group CEO Alastair Smith confident of licensing deals this year

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), tells Proactive's Andrew Scott they've been making significant progress on partnering discussions and he's expecting to deliver at least one substantial licensing deal before its Affimer technology reaches the clinic.

Smith adds that multiple potential pharma and biotech partners are interested in Avacta’s technology.

Quick facts: Avacta Group PLC

Price: £0.21

Market: AIM
Market Cap: £24.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst...

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space. The group's reported interim results to January 2019 today, revealing revenues of...

on 9/4/19

2 min read